Anzeige
Mehr »
Donnerstag, 12.02.2026 - Börsentäglich über 12.000 News
Drohnen, Robotik, E-Autos: Diese Hightech-Aktie könnte jetzt zünden
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
30 Leser
Artikel bewerten:
(0)

Clinical Trials Imaging Market Worth 981.53 Million USD by 2020

PUNE, India, September 23, 2015 /PRNewswire/ --

According to a new market research report "Clinical Trials Imaging Market by Modality (CT, MRI, PET, Ultrasound, Echocardiography, X-rays), End User (Pharmaceutical Companies, CROs Medical device Manufacturers), Product (Services, software), and Region - Global Forecast to 2020", published by MarketsandMarkets, The Clinical Trials Imaging Market expected to reach USD 981.53 Million by 2020, at a CAGR of 6.25%.

Browse 73 market data Tables and 76 Figures spread through 142 Pages and in-depth TOC on "Clinical Trials Imaging Market "

http://www.marketsandmarkets.com/Market-Reports/clinical-trials-imaging-market-30446624.html

Early buyers will receive 10% customization on this report.

The global Clinical Trials Imaging Market is expected to reach USD 981.53 Million by 2020 from USD 724.87 Million in 2015, growing at a CAGR of 6.25%. Growth in pharmaceutical & biotechnology industries increase in R&D funding and increasing number of CROs are the primary growth drivers for this market during the forecast period (2015-2020). However, high implementation cost of imaging systems may hinder the growth of this market.

Ask for PDF Brochure: http://www.marketsandmarkets.com/pdfdownload.asp?id=30446624

The global clinical trials imaging market is segmented on the basis of products, modality and end-users. On the basis of products, the market is segmented into services & software. Of these, the services product segment accounted for the largest share of the global clinical trials imaging market in 2015.

By modality, the market is divided into CT, MRI, ultrasound, PET, X-rays, ECHO and other modalities. Of these, the CT accounted for the largest growing segment in the global clinical trials imaging market by 2020. On the other hand, PET accounted for the fastest growing segment in the global clinical trials imaging market. On the basis of end-users, the clinical trials imaging market is categorized into pharmaceutical companies, biotechnology companies, medical device companies/manufacturers, CROs, academic & government research institutes & other end-users.

The geographic segments included in this report are North America, Europe, Asia, and Rest of the World (RoW).

The major players in this market include BioClinica, Inc. (U.S.), Biomedical Systems (U.S.), Cardiovascular Imaging Technologies (U.S.), ICON Public Limited Company (Ireland), Intrinsic Imaging, LLC (U.S.), IXICO, PLC (U.K.), PAREXEL International Corporation (U.S.), Radiant Sage, LLC (U.S.), VirtualScopic, Inc. (U.S.), and WorldCare Clinical, LLC (U.S.).

Browse Related Reports:

Healthcare Supply Chain Management Market by Product (Inventory Management, Strategic Sourcing, Warehouse Management, Order Management, Supplier Management, RFID & Barcode), Delivery Mode (On Premise, Cloud) & End User - Global Forecast to 2019

http://www.marketsandmarkets.com/Market-Reports/healthcare-supply-chain-management-market-77439622.html

Pre-Clinical Imaging (In-VIVO) Market by Systems and Reagents (Optical Imaging, Micro-PET, Micro-SPECT, Micro-MRI, Micro-ultrasound, Computed Tomography, Photo Acoustic Imaging, Magnetic Particle Imaging, Multimodality Imaging) - Global Forecasts to 2019

http://www.marketsandmarkets.com/Market-Reports/pre-clinical-molecular-imaging-market-841.html

About MarketsandMarkets
MarketsandMarkets is world's No. 2 firm in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to multitude of clients across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets, cutting edge technologies and newer applications. Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors.

M&M's flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. The new included chapters on Methodology and Benchmarking presented with high quality analytical infographics in our reports gives complete visibility of how the numbers have been arrived and defend the accuracy of the numbers.

We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.

Contact:

Mr. Rohan
Markets and Markets
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune, Maharashtra 411013, India
1-888-600-6441
Email: sales@marketsandmarkets.com

Visit MarketsandMarkets Blog @ http://mnmblog.org/market-research/healthcare/healthcareit

Connect with us on LinkedIn @http://www.linkedin.com/company/marketsandmarkets


© 2015 PR Newswire
Favoritenwechsel
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.